首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Saikosaponin A Alleviates Symptoms of Attention Deficit Hyperactivity Disorder through Downregulation of DAT and Enhancing BDNF Expression in Spontaneous Hypertensive Rats
【2h】

Saikosaponin A Alleviates Symptoms of Attention Deficit Hyperactivity Disorder through Downregulation of DAT and Enhancing BDNF Expression in Spontaneous Hypertensive Rats

机译:Saikosaponin A通过下调DAT并增强自发性高血压大鼠的BDNF表达来缓解注意力不足过动症的症状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The disturbed dopamine availability and brain-derived neurotrophic factor (BDNF) expression are due in part to be associated with attention deficit hyperactivity disorder (ADHD). In this study, we investigated the therapeutical effect of saikosaponin a (SSa) isolated from Bupleurum Chinese DC, against spontaneously hypertensive rat (SHR) model of ADHD. Methylphenidate and SSa were orally administered for 3 weeks. Activity was assessed by open-field test and Morris water maze test. Dopamine (DA) and BDNF were determined in specific brain regions. The mRNA or protein expression of tyrosine hydroxylase (TH), dopamine transporter (DAT), and vesicles monoamine transporter (VMAT) was also studied. Both MPH and SSa reduced hyperactivity and improved the spatial learning memory deficit in SHRs. An increased DA concentration in the prefrontal cortex (PFC) and striatum was also observed after treating with the SSa. The increased DA concentration may partially be attributed to the decreased mRNA and protein expression of DAT in PFC while SSa exhibited no significant effects on the mRNA expression of TH and VMAT in PFC of SHRs. In addition, BDNF expression in SHRs was also increased after treating with SSa or MPH. The obtained result suggested that SSa may be a potential drug for treating ADHD.
机译:多巴胺的可用性和脑源性神经营养因子(BDNF)的表达紊乱部分归因于注意力缺陷多动障碍(ADHD)。在这项研究中,我们调查了柴胡皂甙a(SSa)分离自柴胡DC对自发性高血压大鼠(SHR)ADHD的治疗作用。口服哌醋甲酯和SSa 3周。通过露天试验和莫里斯水迷宫试验评估活性。在特定的大脑区域确定了多巴胺(DA)和BDNF。还研究了酪氨酸羟化酶(TH),多巴胺转运蛋白(DAT)和囊泡单胺转运蛋白(VMAT)的mRNA或蛋白质表达。 MPH和SSa均可减少SHR中的多动症并改善空间学习记忆障碍。用SSa处理后,还观察到前额叶皮层(PFC)和纹状体中DA浓度增加。 DA浓度升高可能部分归因于PFC中DAT的mRNA和蛋白表达降低,而SSa对SHRs PFC中TH和VMAT的mRNA表达无明显影响。此外,用SSa或MPH处理后,SHRs中的BDNF表达也增加。所得结果表明SSa可能是治疗ADHD的潜在药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号